{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T02:11:17Z","timestamp":1774491077588,"version":"3.50.1"},"reference-count":87,"publisher":"Informa UK Limited","issue":"8","funder":[{"name":"Scientific Research Flanders","award":["1SD8622N"],"award-info":[{"award-number":["1SD8622N"]}]},{"DOI":"10.13039\/100012331","name":"Flanders Innovation & Entrepreneurship","doi-asserted-by":"crossref","award":["HBC.2021.824"],"award-info":[{"award-number":["HBC.2021.824"]}],"id":[{"id":"10.13039\/100012331","id-type":"DOI","asserted-by":"crossref"}]},{"name":"KU Leuven Industrial Research Fund","award":["C3\/20\/008"],"award-info":[{"award-number":["C3\/20\/008"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anti-infective Therapy"],"published-print":{"date-parts":[[2023,8,3]]},"DOI":"10.1080\/14787210.2023.2233696","type":"journal-article","created":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T12:15:00Z","timestamp":1689336900000},"page":"799-812","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":15,"title":["Oteseconazole: a long-awaited diversification of the antifungal arsenal to manage recurrent vulvovaginal candidiasis (RVVC)"],"prefix":"10.1080","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1181-1090","authenticated-orcid":false,"given":"Paul","family":"Vandecruys","sequence":"first","affiliation":[{"name":"Laboratory of Molecular Cell Biology, Department of Biology, Katholieke Universiteit Leuven, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1763-6868","authenticated-orcid":false,"given":"Silke","family":"Baldewijns","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Cell Biology, Department of Biology, Katholieke Universiteit Leuven, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0555-1181","authenticated-orcid":false,"given":"Mart","family":"Sillen","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Cell Biology, Department of Biology, Katholieke Universiteit Leuven, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8562-8029","authenticated-orcid":false,"given":"Wouter","family":"Van Genechten","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Cell Biology, Department of Biology, Katholieke Universiteit Leuven, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1542-897X","authenticated-orcid":false,"given":"Patrick","family":"Van Dijck","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Cell Biology, Department of Biology, Katholieke Universiteit Leuven, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,7,24]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60917-9"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-010-0137-9"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-2115(00)00289-X"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.5.2155-2162.2005"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199712253372607"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(98)80001-X"},{"key":"cit0007","unstructured":"CDC. Vulvovaginal Candidiasis 2021 [cited 2023 Feb 15]; Available from: https:\/\/www.cdc.gov\/std\/treatment-guidelines\/candidiasis.htm"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00076-09"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30103-8"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-019-05228-3"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-11-169"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2001.115116"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa033114"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2008.06.029"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2008.01523.x"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8628(19971031)72:3<253:AID-AJMG1>3.0.CO;2-S"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199211120-00017"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1002\/bdra.20189"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/22.2.336"},{"key":"cit0020","unstructured":"FDA. FDA Drug Safety Communication: Use Of Long-Term, High-Dose Diflucan (Fluconazole) During Pregnancy May Be Associated With Birth Defects In Infants. 2011 [cited 2023 Feb 16]; Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communicationuse-long-term-high-dose-diflucan-fluconazole-during-pregnancy-may-be"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2009.03.021"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e31827307b2"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1097\/LGT.0000000000000496"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1476490"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-006-0023-7"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.906563"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00833-17"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1097\/LGT.0000000000000383"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05025-11"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00562-21"},{"key":"cit0031","unstructured":"SCYNEXIS, BREXAFEMME\u00ae (ibrexafungerp tablets), for oral use. 2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/214900s002lbl.pdf"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxac256"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.3390\/jof7030163"},{"key":"cit0034","unstructured":"FDA. Novel Drug Approvals For 2022; 2022. [cited 2023 Feb 15]; Available from: https:\/\/www.fda.gov\/drugs\/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products\/novel-drug-approvals-2022"},{"key":"cit0035","unstructured":"Viamet. FORM S-1 REGISTRATION STATEMENT - Viamet Pharmaceuticals Holdings, LCC; 2014. [cited 2023 Feb 20]; Available from: https:\/\/www.sec.gov\/Archives\/edgar\/data\/1538928\/000119312514256344\/d721802ds1.htm"},{"key":"cit0036","unstructured":"HATTERAS. Viamet Pharmaceuticals Raises $4 Million Round Of Financing; 2007. Available from: https:\/\/www.hatterasvp.com\/viamet-pharmaceuticals-raises-4-million-round-of-financing\/"},{"issue":"11","key":"cit0037","first-page":"746","volume":"13","author":"Walker K","year":"2010","journal-title":"IDrugs"},{"key":"cit0038","unstructured":"MycoviaPharmaceuticals, Mycovia Pharmaceuticals And Jiangsu Hengrui Medicine Announce Partnership To Develop And Commercialize VT-1161 For Recurrent Vulvovaginal Candidiasis And Other Fungal Conditions; 2019. Available from: https:\/\/mycovia.com\/wp-content\/uploads\/2022\/01\/Mycovia-and-Hengrui_US-Announcement-on-VT-1161_061719.pdf"},{"key":"cit0039","unstructured":"MycoviaPharmaceuticals, Mycovia Pharmaceuticals Announces Partnership With Gedeon Richter To Commercialize And Manufacture VT-1161 For Recurrent Vulvovaginal Candidiasis; 2019. Available from: https:\/\/mycovia.com\/wp-content\/uploads\/2022\/01\/Mycovia_Richter-License-Release-Final-Approved-for-Distribution_10-15-19.pdf"},{"key":"cit0040","unstructured":"MycoviaPharmaceuticals, Mycovia Pharmaceuticals Submits New Drug Application To The U.S. FDA For Oteseconazole For The Treatment Of Recurrent Vulvovaginal Candidiasis; 2021. Available from: https:\/\/mycovia.com\/wp-content\/uploads\/2022\/01\/MycoviaOteseconazoleNDAsubmissionrelease_MLRapprovedcleanversionFINAL.pdf"},{"key":"cit0041","unstructured":"MycoviaPharmaceuticals, Mycovia Pharmaceuticals Announces U.S. Availability Of VIVJOA\u2122 (Oteseconazole) Capsules, The First And Only FDA-Approved Medication For Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection); 2022. Ava: https:\/\/mycovia.com\/wp-content\/uploads\/2022\/07\/VIVJOA-US-Launch-Press-Release.pdf"},{"key":"cit0042","unstructured":"MycoviaPharmaceuticals, VIVJOA\u2122 (oteseconazole) capsules, for oral use; 2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215888s000lbl.pdf, Editor."},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2014.05.068"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.061562898"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2006.07.018"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.983071"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.2011.607811"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03707-14"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M117.778308"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx352"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab466.916"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01817-16"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00185-15"},{"key":"cit0054","volume-title":"51st Interscience Conference on Antimicrobial Agents and Chemotherapy","author":"Fothergill AW","year":"2011"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00593-15"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1080\/00275514.2021.1913949"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00333-17"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04902-14"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01437-15"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00390-17"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2021-0173"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.28.5.648"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.110.032094"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v7.i11.808"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.115.066795"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01475-4"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2017.01.035"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.2165\/11205480-000000000-00000"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1204"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2018.03.001"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100055"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2022.11.149"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2022.07.023"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01304-19"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00341-19"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02114-18"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1534\/genetics.105.054767"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1128\/EC.3.6.1639-1652.2004"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.2008.06309.x"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1128\/EC.00215-12"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz400"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03470-14"},{"key":"cit0083","volume-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts","author":"CLSI","year":"2017"},{"key":"cit0084","unstructured":"SYNEXIS. SCYNEXIS Presents Positive Data From Its Pivotal Phase 3 CANDLE Study Of Oral Ibrexafungerp For Prevention Of Recurrent Vaginal Yeast Infections During The 2022 IDSOG Annual Meeting. [cit 2022 cit 4]; Available from: https:\/\/d1io3yog0oux5.cloudfront.net\/_b74ab29ee08f7c716ae5e6710e5dba4b\/scynexis\/news\/2022-08-04_SCYNEXIS_Presents_Positive_Data_from_Its_Pivotal_298.pdf"},{"issue":"3","key":"cit0085","first-page":"324","volume":"106","author":"Woolfolk K","year":"2022","journal-title":"Am Fam Physician"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-015-0462-0"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.3390\/jof9020171"}],"container-title":["Expert Review of Anti-infective Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14787210.2023.2233696","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T09:39:01Z","timestamp":1690450741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14787210.2023.2233696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,24]]},"references-count":87,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,3]]}},"alternative-id":["10.1080\/14787210.2023.2233696"],"URL":"https:\/\/doi.org\/10.1080\/14787210.2023.2233696","relation":{},"ISSN":["1478-7210","1744-8336"],"issn-type":[{"value":"1478-7210","type":"print"},{"value":"1744-8336","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-04-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}